BioSpace News Archive

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting agents and immuno-oncology agents and their combination therapies, today announced that APL-102 has received China Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the initiation of a Phase 1 pharmacokinetic

The global macular degeneration treatment market was valued at US$ 6.1 Bn in 2017. It is anticipated to reach US$ 11.1 Bn by 2026, expanding at a CAGR of 6.4% from 2018 to 2026.

The National Institute of Mental Health in the US states that every 1 in 4 adults suffers from a brain disorder every year.

Hypertension is a critical health condition that can lead to cardiovascular diseases, renal failure, stroke, and even death.

Innate Pharma SA, announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.